Brief: EQRx Reports Q3 Loss Of $0.18 Per Share

EQRx

10/11/2022 13:34

Nov 10 (Reuters) - EQRx Inc  EQRX.O :
    * EQRX PROVIDES PORTFOLIO AND U.S. COMMERCIAL STRATEGY
UPDATES;
REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
    * EQRX INC - STRONG FINANCIAL POSITION, $1.5 BILLION CASH
AND
SHORT-TERM INVESTMENTS AT QUARTER-END; ANTICIPATE EXTENDED
RUNWAY INTO 2028
    * EQRX - BASED ON RECENT FDA FEEDBACK, CO HAS CONCLUDED
THERE IS
NO COMMERCIALLY VIABLE PATH FOR SUGEMALIMAB PLUS CHEMOTHERAPY IN
STAGE IV NSCLC IN U.S.
    * EQRX INC - QTRLY LOSS PER SHARE $0.18

Source text for Eikon:  ID:nGNX5NkT5l 
Further company coverage:  EQRX.O 
 ((Reuters.Briefs@thomsonreuters.com;))